The company was founded in 2007 and is a domestic high-tech enterprise focusing on RNA molecular diagnostic technology and products. It is committed to developing and promoting RNA molecular diagnostic products based on real-time fluorescence thermostatic amplification detection technology. Rendu Biotech has a complete set of independent intellectual property core technologies from diagnostic reagents to fully automatic development and production of supporting instruments. The company's main business is R&D, production and sales of molecular diagnostic reagents and equipment integrated products based on the SAT technology platform, focusing on providing solutions for accurate diagnosis, effective prevention, control, and personalized diagnosis and treatment of pathogens in the fields of reproduction, respiration, digestion, hematogenesis, etc. Main products: Reagent products, instrument products, third party medical testing services. The company and its products have been awarded the Ministry of Industry and Information Technology's third batch of “Little Giant” enterprises, Shanghai high-tech enterprises, Shanghai “specialized and new” small and medium-sized enterprises, patent work pilot and demonstration enterprises, Chinese medical device technology innovation enterprises, Ministry of Science and Technology's “Innovative Medical Device Product Catalogue (2018)”, Shanghai High-tech Achievement Transformation Project, “2019/2021 Shanghai Innovative Product Recommendation Catalogue”, the third prize of the Shanghai Science and Technology Award, Shanghai Enterprise Technology Center, and national intellectual property advantage enterprises.
No Data